Sugi Predict

Sugi Predict / Compounds / SCHEMBL196970

SCHEMBL196970

SCHEMBL196970

COc1ccc(Cl)c(OC)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.62
▸ CA1 P00915 2/20 0.62
▸ CA2 P00918 2/20 0.62
▸ CA7 P43166 2/20 0.62
▸ CA9 Q16790 2/20 0.62
▸ CA14 Q9ULX7 2/20 0.62
▸ CYP1A1 P04798 6/20 0.54
▸ CYP1A2 P05177 6/20 0.54
▸ CYP1B1 Q16678 6/20 0.54
▸ ALDH1A1 P00352 5/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ CYP2E1 P05181 1/20 0.48
▸ CYP2C8 P10632 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2A6 P11509 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP4B1 P13584 1/20 0.48
▸ CYP2B6 P20813 1/20 0.48
▸ CYP3A5 P20815 1/20 0.48
▸ CYP2A7 P20853 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29586665 1.00 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL14127254 1.00 CA12 (0.62) CA12CA1CA2CA7CA9
Nitrogen SCHEMBL8497790 0.94 CA12 (0.56) CA12CA1CA2CA7CA9
Isothiocyanate SCHEMBL6157229 0.88 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL15521889 0.83 CA12 (0.43) CA12CA1CA2CA7CA9
SCHEMBL4657288 0.83 GPR84 (0.50) CA12CA1CA2CA7CA9
SCHEMBL262721 0.83 CA12 (0.48) CA12CA1CA2CA7CA9
SCHEMBL13425464 0.81 ALDH1A1 (0.49) ALDH1A1CYP2C9CYP2C19MAPTMEN1
SCHEMBL11217758 0.81 MAOA (0.45) CA12CA1CA2CA7CA9
SCHEMBL197088 0.81 CA12 (0.62) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111362961-B Method for asymmetrically synthesizing optical purity glabridin 玉林师范学院 2021-12-10 — — CN claimed
CN-111362961-A Method for asymmetrically synthesizing optical purity glabridin 玉林师范学院 2020-07-03 — — CN claimed
CN-108794446-A A kind of natural products Agrimonolide extracted from hairyvein agrimony（Ⅰ）The synthesis technology of raceme 中国药科大学 2018-11-13 — — CN claimed
US-20240376058-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2024-11-14 — — US disclosed
US-11912668-B2 GCN2 and perk kinase inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2024-02-27 — — US disclosed
CN-117321037-A GCN2 and PERK kinase inhibitors and methods of use thereof 德西费拉制药有限责任公司 2023-12-29 — — CN disclosed
EP-4247795-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2023-09-27 — — EP disclosed
CN-116730879-A Method for selectively synthesizing 4-amino-N- (hetero) aryl sulfonamide compound 陕西师范大学 2023-09-12 — — CN disclosed
US-20220274934-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2022-09-01 — — US disclosed
WO-2022109001-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2022-05-27 — — WO disclosed
CN-112573978-B High-efficiency halogenation synthesis method of aryl halide 北京大学 2022-05-13 — — CN disclosed
EP-0611766-A1 Polysubstituted 2-amido thiazoles derivatives, process for their preparation, pharmaceutical compositions and utilization for the preparation of a medicament SANOFI (FR) 1994-08-24 — — EP disclosed
EP-0175376-B1 XANTHONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME Chugai Seiyaku Kabushiki Kaisha (JP) 1991-04-03 — — EP disclosed
US-4865619-A Use, as a coupler, of 2,4-diamino-1,3-dimethoxybenzene or one of its salts, in combination with oxidation dye precursors, for dyeing human hair, hair dyeing composition containing the said coupler and process for preparing the said coupler L'OREAL (FR) 1989-09-12 — — US disclosed
US-4816479-A HYPOTENSIVE AGENTS, DIURETICS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1989-03-28 — — US disclosed
US-4714700-A TRANQUILIZERS, ANXIOLYTIC AGENTS CHOAY S.A. (FR) 1987-12-22 — — US disclosed
US-4661607-A ANTIEDEMIC AGENTS, HYPOTENSIVE AGENTS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1987-04-28 — — US disclosed
US-4618459-A INTERMEDIATES FOR BENZENESULFONAMIDE DERIVATIVES; ANTIDEPRESSANTS CHOAY S.A. (FR) 1986-10-21 — — US disclosed
EP-0175376-A2 Xanthone derivatives and process for producing the same Chugai Seiyaku Kabushiki Kaisha (JP) 1986-03-26 — — EP disclosed
US-4457875-A ANTIDEPRESSANTS, TRANQUILIZERS CHOAY S.A. (FR) 1984-07-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376058-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF EIF2AK4, GCN1, EEF2K CA12 4764/4885CA1 4698/4885CA2 3676/4885
US-20220274934-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF EIF2AK4, GCN1, EEF2K CA12 4764/4885CA1 4698/4885CA2 3676/4885
US-11912668-B2 GCN2 and perk kinase inhibitors and methods of use thereof EIF2AK4, GCN1, MAPKAPK2 CA12 4809/4885CA1 4707/4885CA2 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.